%20(1).png){kind=small}
.png){kind=small}
%20(1).png){kind=small}
%20(1)%20(1).png)
The Endocannabinoid System and CBD: An Educational Guide
- Romas Marcin
- May 27
- 9 min read
Updated: Jun 23
Quick takeaway: The endocannabinoid system (ECS) is a biological signaling network found in humans and all other mammals. It's made up of three main components: endocannabinoids (compounds the body produces), cannabinoid receptors (CB1 and CB2), and enzymes that synthesize and break down these compounds. The ECS was first identified in the 1990s and remains an active area of research. CBD interacts with the ECS in multiple ways — though specifics of what these interactions mean for any given person or situation continue to be studied. This guide is educational science content; it's not medical advice.
If you've researched CBD beyond surface-level marketing, you've encountered references to the endocannabinoid system. Understanding what this system is — and what we do and don't yet know about it — provides useful context for how CBD interacts with human biology.
This guide walks through what the ECS is, how it was discovered, its components, how CBD interacts with it, and what's still being researched. We're going to be honest about what's well-established science versus what's still being studied.
What Is the Endocannabinoid System?
The endocannabinoid system is a biological signaling network in the human body (and other mammals) made up of three integrated components:
Endocannabinoids — compounds the body produces naturally that act as signaling molecules
Cannabinoid receptors — proteins on cell surfaces that endocannabinoids bind to
Enzymes — proteins that produce endocannabinoids when needed and break them down when their work is done
These three components work together as part of the body's broader cellular communication system. The ECS is one of many biological signaling networks the body has evolved.
How the Endocannabinoid System Was Discovered
The ECS is a relatively recent discovery in human biology — most components were identified in the 1980s and 1990s, well after THC and CBD themselves were studied.
The timeline:
1964 — THC isolated and characterized by Dr. Raphael Mechoulam
1988 — CB1 receptor identified in mammalian brain tissue
1990 — CB1 receptor successfully cloned
1992 — Anandamide (the first known endocannabinoid) identified by Mechoulam and colleagues
1993 — CB2 receptor identified
1995 — 2-AG (the second major endocannabinoid) identified
The system was named retroactively after the Cannabis sativa plant — the receptors were found while studying how THC interacts with the body. Researchers worked backward to discover the body's own cannabinoid-like compounds.
Why this history matters: the ECS is a young area of research. The system is real and important, but many specifics of how it functions in specific situations remain active areas of study.
The Three Components of the ECS
1. Cannabinoid Receptors
Cell-surface proteins that respond to cannabinoids by signaling cellular changes. The two main types:
CB1 Receptors
Primary location: Central nervous system — concentrated in the brain and along the spinal cord
Also found in: Various peripheral organs and tissues in lower concentrations
Distribution areas include: Regions of the brain involved in various cognitive and physiological processes
Activated by: Endocannabinoids and THC; CBD doesn't bind directly to CB1
CB2 Receptors
Primary location: Peripheral nervous system, immune system tissues, and various organs
Also found in: Throughout the body in lower concentrations
Distribution areas include: Immune system cells and various peripheral tissues
Activated by: Various cannabinoids, with different selectivity than CB1
The distinction between CB1 and CB2 is largely about location and selectivity. Both are part of the broader ECS network.
2. Endocannabinoids
Compounds the body produces naturally that bind to cannabinoid receptors. The two best-studied:
Anandamide (AEA)
Name derives from "ananda," the Sanskrit word meaning "bliss"
First endocannabinoid identified (1992)
Found in higher concentrations in certain body tissues than others
Binds to both CB1 and CB2 receptors
Broken down primarily by the FAAH enzyme
2-AG (2-Arachidonoylglycerol)
Second major endocannabinoid identified (1995)
The most abundant endocannabinoid in the body overall
Binds to both CB1 and CB2 receptors with different selectivity than AEA
Broken down primarily by the MAGL enzyme
The body produces these compounds as needed for signaling, rather than maintaining steady concentrations. They're produced, do their work, and get broken down by enzymes.
3. Metabolic Enzymes
Proteins that produce and break down endocannabinoids. The two most-studied:
FAAH (Fatty Acid Amide Hydrolase)
Primary enzyme for breaking down anandamide
A frequent research target for studying ECS function
MAGL (Monoacylglycerol Lipase)
Primary enzyme for breaking down 2-AG
These enzymes are critical to the ECS because they regulate how long endocannabinoid signals last. Without breakdown, endocannabinoid signaling would persist indefinitely; without production, no signaling would occur.
How CBD Interacts with the ECS
This is where research becomes more nuanced. Unlike THC, which binds directly and strongly to CB1 receptors, CBD's interactions with the ECS are more indirect:
CBD Doesn't Bind Directly to CB1 or CB2
CBD has relatively low affinity for both CB1 and CB2 receptors compared to THC or even the body's own endocannabinoids. It doesn't function as a typical receptor agonist or antagonist for these receptors.
CBD May Affect How Endocannabinoids Are Broken Down
Research suggests CBD may influence how the FAAH enzyme processes anandamide. By potentially affecting FAAH activity, CBD might allow anandamide to remain active in the system longer than it would otherwise. This is one of the more studied mechanisms for how CBD might affect ECS function indirectly.
CBD Interacts With Other Receptor Systems
CBD has documented interactions with several other receptor systems beyond just CB1 and CB2:
Serotonin receptors (particularly 5-HT1A)
TRP channels (TRPV1, TRPA1)
Adenosine receptors
PPAR receptors
GPR55 and various other G-protein coupled receptors
These interactions are still being studied. Many of CBD's biological effects may come through these other receptor systems rather than direct ECS interaction.
The Honest Summary
CBD interacts with the ECS in real, measurable ways — but the specific biological consequences of those interactions are still being mapped by researchers. The "CBD activates your ECS to do X" narratives common in CBD marketing tend to overstate how settled this science is.
The "Endocannabinoid Tone" Theory
You may encounter references to "endocannabinoid tone" or "clinical endocannabinoid deficiency" in CBD content. This concept deserves honest treatment:
What the Theory Proposes
The endocannabinoid deficiency theory, proposed by Dr. Ethan Russo in 2004, suggests that some chronic conditions might be associated with lower endocannabinoid system activity than optimal. The theory hypothesizes that supporting ECS function might be relevant for these conditions.
What Research Shows
Some research supports aspects of the theory:
Studies have measured endocannabinoid levels in various conditions
Some conditions show altered endocannabinoid profiles
Aspects of the theory remain plausible based on existing evidence
Other research is more skeptical:
"Endocannabinoid deficiency" isn't a clinically recognized diagnosis
The relationships between endocannabinoid levels and various conditions remain incompletely understood
The theory has been more popularized in cannabis education than fully established in mainstream medical research
Honest Framing
Endocannabinoid tone/deficiency is a plausible scientific hypothesis with partial research support rather than established medical fact. Like the entourage effect, it's a concept that's become more popularized in CBD marketing than the underlying research warrants.
For more on similar topics where CBD science theory and marketing diverge, see our Entourage Effect guide.
What Research Has and Hasn't Established
Honest framing requires acknowledging what's not yet settled about ECS research:
Better established:
The basic structure of the ECS (receptors, endocannabinoids, enzymes)
How various compounds bind to cannabinoid receptors at the molecular level
The presence of the ECS across mammalian species
General involvement of the ECS in various biological processes
Less established or still being studied:
Exactly how ECS dysregulation contributes to specific health conditions
Precise effects of various CBD doses on ECS function in different people
How endocannabinoid tone varies across populations and conditions
Long-term effects of supplementing with CBD or other phytocannabinoids
Optimal cannabinoid-receptor interaction profiles for various wellness goals
This isn't a weakness of CBD as a category — it's an honest reflection of where cannabinoid research currently stands. Cannabis was federally prohibited from 1937 until 2018, which dramatically limited mainstream research during the formative decades when other compound classes were being thoroughly studied.
ECS in Other Mammals
Humans aren't unique in having an endocannabinoid system. All mammals have an ECS — dogs, cats, horses, cows, and others — with broadly similar biology to humans. This is why CBD is biologically relevant across species, not just for humans.
For pet-focused ECS content, see our Endocannabinoid System in Animals guide.
What This Means for CBD Consumers
For practical purposes, here's how to think about the ECS in relation to CBD products:
The ECS is real biology, not a marketing concept
CBD does interact with the ECS in measurable ways
The specific biological consequences of those interactions remain an active research area
Be skeptical of overclaims about exactly what CBD does through the ECS
Quality and verification matter — whatever CBD does biologically, you need to know your product actually contains what it claims
The most honest position is: the ECS provides interesting context for why CBD might affect biology, but doesn't constitute proof of any specific outcome. For most consumer purposes, ECS biology is more useful as background education than as a basis for specific product claims.
Frequently Asked Questions
What is the endocannabinoid system?
The endocannabinoid system (ECS) is a biological signaling network found in humans and other mammals. It's made up of endocannabinoids (compounds the body produces), cannabinoid receptors (CB1 and CB2), and enzymes that synthesize and break down these compounds. It was first identified in the 1990s.
When was the ECS discovered?
The ECS was identified through research between 1988 and 1995. CB1 receptors were discovered in 1988, anandamide (the first known endocannabinoid) was identified in 1992, CB2 receptors were identified in 1993, and 2-AG was identified in 1995. The system is named after the cannabis plant because cannabis research led to its discovery.
What are CB1 and CB2 receptors?
CB1 and CB2 are the two primary cannabinoid receptors. CB1 receptors are concentrated in the central nervous system (brain and spinal cord). CB2 receptors are concentrated in the peripheral nervous system, immune system tissues, and various organs. Both receptor types exist throughout the body in varying concentrations.
What are AEA and 2-AG?
AEA (anandamide) and 2-AG (2-arachidonoylglycerol) are the two main endocannabinoids — compounds the body produces naturally that bind to cannabinoid receptors. AEA was identified first (1992), 2-AG second (1995). They're produced as needed for biological signaling rather than maintained at steady levels.
Does CBD bind to cannabinoid receptors?
CBD has relatively low affinity for CB1 and CB2 receptors compared to THC or the body's own endocannabinoids. CBD interacts with the ECS more indirectly — possibly by affecting how the FAAH enzyme breaks down anandamide. CBD also interacts with several other receptor systems beyond just CB1 and CB2.
What is endocannabinoid tone?
Endocannabinoid tone refers to the overall activity level of the endocannabinoid system. The concept was developed alongside the "endocannabinoid deficiency theory," which proposes that some conditions might be associated with lower ECS activity. The theory has some research support but isn't established medical fact.
Is endocannabinoid deficiency a real condition?
"Endocannabinoid deficiency" is a theoretical concept proposed by Dr. Ethan Russo in 2004. It has some research support and remains a plausible hypothesis, but it isn't a clinically recognized medical diagnosis. The theory has become more popular in cannabis education than fully established in mainstream medical research.
What does the ECS do?
The ECS is involved in various biological signaling processes. The specifics of which processes are most affected and how vary across the body and across situations. Research is ongoing. Honest framing acknowledges that the ECS is real and important, but the precise details of what it does in any given context remain incompletely understood.
Do other animals have an endocannabinoid system?
Yes. All mammals have an ECS — dogs, cats, horses, and others. The biology is broadly similar across mammalian species, with some species-specific variations. This is why CBD has been studied across multiple species.
How does CBD interact with the ECS?
CBD interacts with the ECS in multiple indirect ways. Unlike THC, CBD doesn't bind strongly to CB1 receptors. Instead, CBD may affect enzyme activity (particularly FAAH, which breaks down anandamide) and interacts with several other receptor systems beyond CB1 and CB2. The full picture of CBD's biological effects remains an active research area.
Final Thoughts
The endocannabinoid system is one of the most interesting discoveries in modern human biology — a regulatory network that wasn't recognized as a system until the 1990s but appears throughout the body and across mammalian species.
For CBD consumers, the ECS provides useful context: it explains why cannabis-derived compounds are biologically relevant rather than inert. But the ECS doesn't prove specific health outcomes from CBD use. That's a different research question, and one that's still being worked out.
The honest position is: real biology, real interactions, real research happening — but consumer claims based on ECS biology should be considered carefully rather than accepted at face value.
About the Author
Romas Marcin — Founder, GoGreen Hemp
Romas founded GoGreen Hemp in 2016 and has spent nearly a decade studying cannabinoids, the endocannabinoid system, and the hemp industry. He leads product development and quality standards across all GoGreen Hemp products, with a particular interest in honest scientific communication around how cannabinoids and the ECS actually interact based on current research.
These statements have not been evaluated by the Food and Drug Administration. Hemp-derived products are not intended to diagnose, treat, cure, or prevent any disease or condition. This article provides general scientific and educational information; it is not medical advice.
Comments